Publicacións en colaboración con investigadores/as de Hospital Universitari de Bellvitge (4)

2024

  1. BRAF mutational status is associated with survival outcomes in locally advanced resectable and metastatic NSCLC

    Lung Cancer, Vol. 194

2021

  1. Comprehensive cross-platform comparison of methods for non-invasive EGFR mutation testing: results of the RING observational trial

    Molecular Oncology, Vol. 15, Núm. 1, pp. 43-56

2016

  1. Bevacizumab and temozolomide versus temozolomide alone as neoadjuvant treatment in unresected glioblastoma: the GENOM 009 randomized phase II trial

    Journal of Neuro-Oncology, Vol. 127, Núm. 3, pp. 569-579

2012

  1. Multicenter, phase II, nonrandomized study of docetaxel plus trastuzumab every 21 days as the primary therapy in metastatic breast cancer overexpressing HER2

    Anti-Cancer Drugs, Vol. 23, Núm. 2, pp. 239-246